IT1258491B - Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi. - Google Patents

Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.

Info

Publication number
IT1258491B
IT1258491B ITRM920693A ITRM920693A IT1258491B IT 1258491 B IT1258491 B IT 1258491B IT RM920693 A ITRM920693 A IT RM920693A IT RM920693 A ITRM920693 A IT RM920693A IT 1258491 B IT1258491 B IT 1258491B
Authority
IT
Italy
Prior art keywords
carnitine
patients
aids
treatment
related syndromes
Prior art date
Application number
ITRM920693A
Other languages
English (en)
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of ITRM920693A0 publication Critical patent/ITRM920693A0/it
Priority to ITRM920693A priority Critical patent/IT1258491B/it
Priority to ZA936300A priority patent/ZA936300B/xx
Priority to AT93114235T priority patent/ATE160090T1/de
Priority to ES93114235T priority patent/ES2110551T3/es
Priority to EP93114235A priority patent/EP0590355B1/en
Priority to DK93114235.0T priority patent/DK0590355T3/da
Priority to DE69315162T priority patent/DE69315162T2/de
Priority to KR1019930018520A priority patent/KR0136559B1/ko
Priority to JP5237790A priority patent/JPH06227983A/ja
Publication of ITRM920693A1 publication Critical patent/ITRM920693A1/it
Priority to US08/370,357 priority patent/US5631288A/en
Application granted granted Critical
Publication of IT1258491B publication Critical patent/IT1258491B/it
Priority to GR970402512T priority patent/GR3025372T3/el
Priority to HK98104022A priority patent/HK1004910A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Viene descritto un nuovo uso terapeutico della L-carnitina, acil L-carnitine e loro sali farmacologicamente accettabili nel trattamento delle alterazioni immunologiche e metaboliche in pazienti affetti da AIDS e sindromi correlate e di pazienti asintomatici HIV-sieropositivi.Per tale uso, la quantità di L-carnitina da somministrare è di circa 6-8 grammi al giorno (per via orale) o una quantità equivalente di acil L-carnitina o di un suo sale farmacologicamente accettabile, cioè tre-quattro volte la dose normalmente somministrata per gli usi terapeutici già noti della L-carnitina.
ITRM920693A 1992-09-24 1992-09-24 Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi. IT1258491B (it)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ITRM920693A IT1258491B (it) 1992-09-24 1992-09-24 Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.
ZA936300A ZA936300B (en) 1992-09-24 1993-08-27 Use of L-carnitine and acyl L-carnitines for treating patients suffering from AIDS and AIDS-related syndromes and asymptomatic HIV-seropositive patients
DE69315162T DE69315162T2 (de) 1992-09-24 1993-09-06 Verwendung von L-Carnitine und Acyl-L-Carnitinen zur Behandlung von Patienten die an AIDS-verwandten Syndromen leiden und von asymptomatischen HIV-seropositiven Patienten
ES93114235T ES2110551T3 (es) 1992-09-24 1993-09-06 Empleo de l-carnitina y acil l-carnitinas para tratamiento de pacientes que padecen sindromes relacionados con el sida y pacientes de hiv seropositivos asintomaticos.
EP93114235A EP0590355B1 (en) 1992-09-24 1993-09-06 Use of L-carnitine and acyl L-carnitines for treating patients suffering from aids-related syndromes and asymptomatic HIV-seropositive patients
DK93114235.0T DK0590355T3 (da) 1992-09-24 1993-09-06 Anvendelse af L-carnitin og acyl-L-carnitiner til behandling af patienter, der lider af AIDS-relaterede syndromer og asymptomatiske HIV-seropositive patienter
AT93114235T ATE160090T1 (de) 1992-09-24 1993-09-06 Verwendung von l-carnitine und acyl-l-carnitinen zur behandlung von patienten die an aids- verwandten syndromen leiden und von asymptomatischen hiv-seropositiven patienten
KR1019930018520A KR0136559B1 (ko) 1992-09-24 1993-09-13 에이즈 및 에이즈 관련 증후군 환자 및 무증후성 hiv 혈청양성 환자 치료를 위한 l-카르니틴 및 아실 l-카르니틴의 용도
JP5237790A JPH06227983A (ja) 1992-09-24 1993-09-24 エイズ治療のためのｌ−カルニチン類の使用
US08/370,357 US5631288A (en) 1992-09-24 1995-01-09 Therapeutic method of treating patients suffering from AIDS and AIDS-related syndromes and asymptomatic HIV-seropositive patients.
GR970402512T GR3025372T3 (en) 1992-09-24 1997-11-13 Use of l-carnitine and acyl l-carnitines for treating patients suffering from aids-related syndromes and asymptomatic hiv-seropositive patients
HK98104022A HK1004910A1 (en) 1992-09-24 1998-05-09 Use of l-carnitine and acyl l-carnitines for treating patients suffering from aids-related syndromes and asymptomatic hiv-seropositive patients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM920693A IT1258491B (it) 1992-09-24 1992-09-24 Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.

Publications (3)

Publication Number Publication Date
ITRM920693A0 ITRM920693A0 (it) 1992-09-24
ITRM920693A1 ITRM920693A1 (it) 1994-03-24
IT1258491B true IT1258491B (it) 1996-02-26

Family

ID=11401203

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM920693A IT1258491B (it) 1992-09-24 1992-09-24 Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.

Country Status (12)

Country Link
US (1) US5631288A (it)
EP (1) EP0590355B1 (it)
JP (1) JPH06227983A (it)
KR (1) KR0136559B1 (it)
AT (1) ATE160090T1 (it)
DE (1) DE69315162T2 (it)
DK (1) DK0590355T3 (it)
ES (1) ES2110551T3 (it)
GR (1) GR3025372T3 (it)
HK (1) HK1004910A1 (it)
IT (1) IT1258491B (it)
ZA (1) ZA936300B (it)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000137A1 (de) * 1993-06-21 1995-01-05 Bernardini, Attilio Verwendung von acylcarnitin zur behandlund von aids-krankheiten
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20080119386A1 (en) * 2006-11-22 2008-05-22 Carl Germano Nutritional formula for athletes' recovery
CA2681158C (en) 2007-03-13 2018-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US11865121B2 (en) 2016-02-11 2024-01-09 Nutrition21, LLC Chromium containing compositions for improving health and fitness

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1143214B (it) * 1981-07-09 1986-10-22 Sigma Tau Ind Farmaceuti Acil derivato della carnitina quale immunomodulatore
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
US5272153A (en) * 1986-12-31 1993-12-21 Hoechst-Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease

Also Published As

Publication number Publication date
ATE160090T1 (de) 1997-11-15
KR940006576A (ko) 1994-04-25
JPH06227983A (ja) 1994-08-16
ITRM920693A0 (it) 1992-09-24
GR3025372T3 (en) 1998-02-27
EP0590355A1 (en) 1994-04-06
HK1004910A1 (en) 1998-12-11
EP0590355B1 (en) 1997-11-12
US5631288A (en) 1997-05-20
ES2110551T3 (es) 1998-02-16
ITRM920693A1 (it) 1994-03-24
DE69315162T2 (de) 1998-03-12
KR0136559B1 (ko) 1998-04-25
ZA936300B (en) 1995-02-27
DE69315162D1 (de) 1997-12-18
DK0590355T3 (da) 1998-03-02

Similar Documents

Publication Publication Date Title
ES2172510T3 (es) Nueva combinacion de formoterol y budesonida.
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
DK1030670T3 (da) Anvendelse af vitamin D-derivater til forstærkning af virkningen af cytotoksiske midler
ES2094823T3 (es) Pasta dentifrica antimicrobiana.
ATE225649T1 (de) Arzneizubereitung bestehend aus rhein oder diacerhein mit verbesserter bioverfügbarkeit
DE69331409T2 (de) Oral 1alpha-hydroxyprevitamin d
IT1258491B (it) Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.
IT1263004B (it) Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
AR040709A1 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
IT1256651B (it) Composizione farmaceutica a rilascio controllato in sospensione liquida
IT1252692B (it) Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
IT1245699B (it) Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi
IT1244636B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
GR1000419B (el) Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου.
ES2109131B1 (es) Composicion farmaceutica que tiene actividad analgesica.
IT1254314B (it) Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
MX9304365A (es) Una forma de dosis osmotica para administrar tandospirona.
ITRM910435A1 (it) Preparato farmaceutico da utilizzare quale trattamento coadiuvante della dermatite seborroica anche in soggetti hiv positivi
AR027624A1 (es) Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos
IT1229489B (it) Composizioni farmaceutiche lipidiche per uso topico atte a veicolare un principio attivo antiinfiammatorio idrosolubile
IE44461L (en) Piperazinyluracil salts
IT1263222B (it) Composizione farmaceutica per la somministrazione attraverso le mucose.
AR007058A1 (es) Uso de interferon en medicamentos y composiciones para contacto oromucosal
RU2005131643A (ru) Способ лечения рецидивирующего герпетического стоматита, осложненного соматоформным болевым расстройством

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970709